Do We Need a GAVI For Diagnostics in the Developing World?

Tuesday, 2 October 2018 at 17:15

Add to Calendar ▼2018-10-02 17:15:002018-10-02 18:15:00Europe/LondonDo We Need a GAVI For Diagnostics in the Developing World?Point-of-Care Diagnostics and Global Health 2018 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Silos are the chief impediment to progress in global health. Technology innovation is needed, but not sufficient to achieve impact. Adopting an “end-to-end” strategy requires deep knowledge and connectiveness among supply, demand, and facilitating stakeholders. GAVI, The Vaccine Alliance, provides a model that might work for diagnostics.

Jim Gallarda, Senior Program Officer, Bill & Melinda Gates Foundation

Jim Gallarda

Jim Gallarda, Senior Program Officer, ITS, oversees the diagnostic portfolio for the TB PST, and serves as a resource for all foundation diagnostic needs related to molecular technologies. Jim brings systems-level end-to-end thinking in diagnostic-related R&D, clinical, regulatory, and commercialization, both in the developed & developing world.

Jim has a 20-year background in industry developing in vitro diagnostics at Abbott & Roche. He is experienced in blood screening infectious disease assay development, overseeing multiple teams developing immunodiagnostic & PCR systems for HIV-1, HIV-2, HCV, HBV and WNV. Prior to joining the Bill & Melinda Gates Foundation he was with Novartis Pharmaceuticals (in Cambridge MA) leading companion diagnostics program for assays used to assess the effectiveness of tyrosine kinase inhibitors for patients with CML.